OUR REACH
Horizon positions issues at the forefront of the national conversation on healthcare by cutting through political noise to drive the health agenda.
Our team is a recognized, trusted source for the latest health policy information and analysis by top tier national publications, trade press, and regional media outlets.
On Health Policy, Donald Trump Beats Joe Biden Hands Down
Joel White published an opinion piece that examines the differences between the Democratic and Republican philosophies in their approach to governing through the lens of healthcare.
Joel White's Op-Ed
Democrats’ Long-Sought Plan for Lowering Drug Costs Is at Hand
Ten drugs would qualify for negotiation in 2026, with more added in subsequent years. The bill outlines criteria by which the drugs would be chosen, but the ultimate decision would rest with the health secretary — a provision that Joel White, Republican health policy consultant, warned would lead to ‘an incredible lobbying campaign’ to get drugs on the list or keep them off it.
Florida Could Put Canadian Drugs on Shelves 90 Days After Federal Import Approval
Joel White challenges Governor DeSantis’s plan to import drugs from Canada, saying it “brings a false promise to Americans that it will result in lower cost.”
Drug-Price Negotiation Could Survive a Trump-Vance Administration
Joel White was interview by the National Journal about what another Trump presidency could mean for the Inflation Reduction Act and it’s forced drug pricing negotiations.
White discussed options the Trump administration could use to pass on savings to patients.
Briefing Members of Congress on Expanding Jobs-Based Coverage for Small Businesses
Joel White participated in a roundtable hosted by Education and Labor Committee Republican Leader Virginia Foxx (R-N.C.). The panel discussed efforts to fix the family glitch and efforts to stop efforts by the Administration to push more Americans onto government-controlled insurance.
Democrats Try to Break Through on Drug Pricing Message
"Less than a month to the election, you’re going to talk about something you’re gonna give me in two years, or three years or four years. And I’m hurting right now," said Joel White, a health care industry consultant and former House GOP staffer.
Lag in Biden’s NIH Nominee Creates Tougher Confirmation Scenario
It’s incredibly important to have someone, Brett Meeks, a vice president at Horizon Government Affairs. You have a lot of money that goes through NIH for important research. And we’re still in the middle of a public health emergency with others potentially on the horizon.
Reforms Are Needed to Rein In Health Spending, But Reference Pricing Isn’t Worth The Risk
In a joint op-ed, Joel White outlines how a legislative push to introduce international reference pricing on prescription drugs would gravely impact future innovation and patient outcomes.
